| |
Stay ahead in AAV gene therapy—uncover vital strategies for immunogenicity assessment and companion diagnostics (CDx) approval.
Discover Key Strategies Now.
|
|
Today’s Big NewsFeb 21, 2025 |
|
| Wednesday, February 26, 2025 | 12pm ET / 9am PTIn today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome these challenges using AI cloud infrastructure and advanced machine learning tools. |
|
| By Darren Incorvaia A slimmed-down BioMarin started the new year open for business, seeking to leverage its unique skillset to strike deals that bolster its pipeline of medicines for genetic diseases. |
|
|
|
By Gabrielle Masson The Trump administration is exploiting an administrative loophole to keep federal research funding frozen, despite a federal judge ordering for a halt to the action, according to Nature. |
By Darren Incorvaia Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene therapy, data that is prompting the biotech to seek accelerated approval in AIPL1-associated severe retinal dystrophy. |
Sponsored by Grifols Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor symptoms that significantly affects patients and their loved ones. |
By James Waldron Acelyrin had been all set to merge into Alumis—but a surprise offer by Concentra Biosciences has thrown the deal into doubt. |
By Gabrielle Masson After announcing acquisition plans at the beginning of 2025, immunotherapeutics biotech Hookipa Pharma has decided not to buy rare disease company Poolbeg Pharma. |
By Darren Incorvaia,Zoey Becker The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies. |
By Andrea Park,James Waldron,Gabrielle Masson This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
By Angus Liu Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez. The move leaves no active gene therapy programs in Pfizer's portfolio. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Angus Liu Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing deal worth up to $1.3 billion. AstraZeneca is buying out its roxadustat partner FibroGen in China. Ono Pharmaceutical's $2.4 billion Deciphera acquisition has borne fruit. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
|
|---|
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
